Swallowed topical corticosteroids and proton pump inhibitors have historically been the mainstays of medical therapy for EoE. Several new classes of treatment are now in development and the therapeutic landscape is anticipated to change drastically over the next decade.

Presentations from our experts will span basic science to clinical trials covering topics including:

• An overview of current and future therapeutic targets in EoE
• Advancements in existing EoE drug development programs
• The evolution in assessment of endoscopic and histologic disease activity in EoE
• The importance of patient-reported outcomes in EoE
• The pipeline for drug development in EoE